Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Lanraplenib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kronos Begins Dosing in PIb/II Trial of Lanraplenib with Gilteritinib
    Kronos Begins Dosing in PIb/II Trial of Lanraplenib with Gilteritinib

    22 Aug 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/08/22/2502156/0/en/Kronos-Bio-Announces-First-Patient-Dosed-in-Phase-1b-2-Clinical-Trial-of-Lanraplenib-in-Combination-with-Gilteritinib-in-Acute-Myeloid-Leukemia.html

    GLOBENEWSWIRE
    22 Aug 2022
    Share Share
    Kronos Bio's SYK Inhibitors Entospletinib and Lanraplenib at EHA 2022
    Kronos Bio's SYK Inhibitors Entospletinib and Lanraplenib at EHA 2022

    12 May 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/05/12/2442168/0/en/Kronos-Bio-s-Investigational-SYK-Inhibitors-Entospletinib-and-Lanraplenib-to-be-Featured-in-Four-Poster-Presentations-at-EHA2022-Congress.html

    GLOBENEWSWIRE
    12 May 2022
    Share Share